QURE - NASDAQ
uniQure N.V.
$29.88
+12%uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
At a Glance
Live SnapshotuniQure N.V. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
uniQure N.V. Cash Flow Statement
QURE • NASDAQ
| uniQure N.V. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-199M | -239.6M | -308.5M | -126.8M | 329.6M | -125M | -124.2M | -83.3M | -80.4M | -73.4M | -78.1M | -45M | -37M | -19.5M | -22.4M | |
14.8M | 12.6M | 11.9M | 8.5M | 7.3M | 10.6M | 6.7M | 12.4M | 8.3M | 6.1M | 4.9M | 1.9M | 738.8K | 724.7K | 764.7K | |
1.6M | 2.4M | 1.9M | -1.5M | 3.2M | -16.4M | 0.0 | 231K | 209K | 1.1M | -523.7K | -7.3M | 3.6M | 633.5K | 151.6K | |
17.7M | 22.3M | 35.1M | 34.2M | 25.6M | 21.8M | 17.5M | 10.7M | 10.1M | 6.2M | 8.3M | 11.5M | 2.8M | 2.3M | 1.2M | |
-6.2M | 23.4M | 32.5M | -16.2M | -27.3M | -19.4M | 3.4M | -9.9M | 10.1M | -2M | 16.1M | 8.6M | 1.9M | 80.7K | 473.1K | |
-6.8M | -3.9M | 81.1M | -43.4M | -50.5M | -6.5M | -2.1M | -6.2M | -12.7M | -10.3M | 68.2M | -548.4K | 22.3M | 772.3K | -1.8M | |
-178M | -182.7M | -145.9M | -145.1M | 288M | -134.8M | -98.7M | -76M | -64.3M | -72.2M | 18.8M | -30.9M | -5.7M | -14.9M | -21.7M | |
INVESTING ACTIVITIES | |||||||||||||||
-439K | -11.7M | -7.2M | -17.7M | -17.4M | -7.3M | -6.6M | -4.2M | -5.6M | -17.2M | -9.4M | -23.3M | -8.3M | -1.2M | -400.5K | |
(0.0) | (0.0) | (0.0) | -1.9M | -49.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1.8M | (0.0) | (0.0) | (0.0) | |
-658.4M | -359.8M | -366.4M | -163.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -613K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
337.2M | 534.5M | 167.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.2M | 0.0 | -1.9M | -567K | -613K | 99.5K | 180K | 23.5K | 149.4K | 190.5K | |
-321.6M | (163M) | -205.7M | -182.7M | -67.4M | -9.5M | -6.6M | -4.2M | -6.2M | -17.8M | -9.3M | -24.9M | -8.2M | -1.1M | -210K | |
FINANCING ACTIVITIES | |||||||||||||||
391.9M | 2.1M | 308K | 1.4M | 33.7M | 7.4M | 242.7M | 138.4M | 85.3M | 0.0 | 158M | 85.1M | 19.7M | 12.9M | 140K | |
0.0 | -53.1M | 370.1M | 0.0 | 62.5M | 0.0 | 0.0 | 14.8M | 0.0 | -148K | -186K | 9.3M | 25.7M | 0.0 | 0.0 | |
23.5M | -8.6M | -7.6M | 0.0 | -1.3M | 0.0 | 6.1M | 4.8M | 4.8M | 2.6M | 2.9M | 0.0 | -761.2K | 2.3M | 0.0 | |
415.4M | -59.5M | 362.7M | 1.4M | 94.9M | 7.4M | 248.8M | 158M | 90.1M | 2.4M | 150.4M | 84.5M | 46.5M | 14.9M | 140K | |
CASH FLOW SUMMARY | |||||||||||||||
5.5M | -5M | 2.3M | -1.8M | -3.8M | 3.8M | -106K | -2.2M | 7.2M | -1.6M | 4.5M | 7.1M | 16.6K | 0.0 | 0.0 | |
-78.7M | -84.2M | 13.4M | -328.2M | 311.7M | -133M | 143.4M | 75.5M | 26.9M | -89.1M | 164.3M | 35.8M | 32.5M | -1.1M | -21.7M | |
158.9M | 244.5M | 231.2M | 559.4M | 247.7M | 380.7M | 237.3M | 161.9M | 132.5M | 221.6M | 58.2M | 29M | 363.2K | 1.5M | 23.1M | |
80.2M | 160.3M | 244.5M | 231.2M | 559.4M | 247.7M | 380.7M | 237.3M | 159.4M | 132.5M | 222.5M | 64.7M | 32.9M | 347.8K | 1.4M | |
-178M | -186.1M | -153.1M | -162.7M | 270.5M | -144.3M | -105.3M | -80.3M | -69.9M | -89.4M | 9.4M | -54.2M | -14M | -16.2M | -22.1M |
SEC Filings
QURE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 |
Related Guides
Continue your QURE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.